{"title":"Kidney Cancer","description":null,"products":[{"product_id":"lyvioni-lenvatinib-4","title":"Lyvioni-4 (Lenvatinib)","description":"Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\r\n\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\r\n\r\n24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\r\n\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_everolimus\"\u003eCombination therapy with everolimus\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\r\n \t\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_pembrolizumab\"\u003eCombination therapy with pembrolizumab\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\r\n \t\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\r\n\u003ch4\u003e\u003cspan id=\"Dose_based_on_actual_body_weight\"\u003eDose based on actual body weight\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e\u003cspan id=\"Endometrial_Cancer\"\u003eEndometrial Cancer\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\r\n\r\n20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\r\nRefer to pembrolizumab prescribing information for recommended dosing information\r\n\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"DTC_dose_reductions\"\u003eDTC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"RCC_or_endometrial_carcinoma_dose_reductions\"\u003eRCC or endometrial carcinoma dose reductions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_everolimus_in_RCC\"\u003eDose modification of everolimus in RCC\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_pembrolizumab_in_endometrial_carcinoma\"\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\r\n \t\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"HCC_dose_reductions\"\u003eHCC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"First_occurrence\"\u003eFirst occurrence\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Second_occurrence\"\u003eSecond occurrence\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Third_occurrence\"\u003eThird occurrence\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hypertension\"\u003eHypertension\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Cardiac_dysfunction\"\u003eCardiac dysfunction\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Arterial_thrombotic_event\"\u003eArterial thrombotic event\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Proteinuria\"\u003eProteinuria\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\r\n \t\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"GI_toxicity\"\u003eGI toxicity\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Renal_failure_or_impairment\"\u003eRenal failure or impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Reversible_posterior_leukoencephalopathy_syndrome_RPLS\"\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Severe_CrCl_30_mLmin\"\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Severe_Child-Pugh_C\"\u003eSevere (Child-Pugh C)\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946658859,"sku":"RL142023090152","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663298393-8916879d1cfb675.png?v=1787022078"},{"product_id":"lenvima-lenvatinib-4mg","title":"Lyvioni-10 (Lenvatinib)","description":"Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\r\n\u003ch3\u003eDifferentiated Thyroid Cancer\u003c\/h3\u003e\r\nIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\r\n\r\n24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\r\n\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\r\n\u003ch4\u003eCombination therapy with everolimus\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\r\n \t\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCombination therapy with pembrolizumab\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\r\n \t\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHepatocellular Carcinoma\u003c\/h3\u003e\r\nIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\r\n\u003ch4\u003eDose based on actual body weight\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eEndometrial Cancer\u003c\/h3\u003e\r\nIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\r\n\r\n20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\r\nRefer to pembrolizumab prescribing information for recommended dosing information\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDTC dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRCC or endometrial carcinoma dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eDose modification of everolimus in RCC\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\r\n \t\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHCC dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eFirst occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSecond occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eThird occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHypertension\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCardiac dysfunction\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eArterial thrombotic event\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHepatoxicity\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eProteinuria\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\r\n \t\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eGI toxicity\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRenal failure or impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eQTc prolongation\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRenal impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSevere (Child-Pugh C)\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946953771,"sku":"RL1420230901138","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1767.jpg?v=1787022083"},{"product_id":"cabonni-cabozantinib-80mg","title":"Cabonni 20 (Cabozantinib)","description":"\u003cdiv class=\"page-header\"\u003e\r\n\u003cdiv class=\"headers v2 lg\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv id=\"main-content\" role=\"main\"\u003e\r\n\u003ch2\u003eDescription\u003c\/h2\u003e\r\n\u003cstrong\u003eCabonni (Cabozantinib) \u003c\/strong\u003ecapsule is used to treat medullary thyroid cancer that has already spread to different parts of the body.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is used alone to treat advanced kidney cancer. It is also used in combination with nivolumab as first-line treatment for advanced kidney cancer.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is also used to treat a type of liver cancer, called hepatocellular carcinoma, in patients who have been previously treated with other medicines (eg, sorafenib).\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is also used to treat differentiated thyroid cancer that has already spread to different parts of the body, in patients who can no longer be treated with radioactive iodine or not able to receive radioactive iodine, and have been previously treated with other medicines (eg, VEGFR-targeted treatment) but did not work well.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e is an antineoplastic (cancer) medicine. It interferes with the growth of cancer cells, which are eventually destroyed by the body.\r\n\r\nThis medicine is available only with your doctor's prescription.\r\n\r\nThis product is available in the following dosage forms:\r\n\u003cul\u003e\r\n \t\u003cli\u003eCapsule\u003c\/li\u003e\r\n \t\u003cli\u003eTablet\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eBefore Using\u003c\/h2\u003e\r\nIn deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:\r\n\u003ch3\u003eAllergies\u003c\/h3\u003e\r\nTell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.\r\n\u003ch3\u003ePediatric\u003c\/h3\u003e\r\nAppropriate studies have not been performed on the relationship of age to the effects of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e in children younger than 12 years of age to treat differentiated thyroid cancer or in children to treat medullary thyroid cancer, liver cancer, and advanced kidney cancer. Safety and efficacy have not been established.\r\n\u003ch3\u003eGeriatric\u003c\/h3\u003e\r\nAppropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablets in the elderly.\r\n\r\nAppropriate studies have not been performed on the relationship of age to the effects of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e capsules in the geriatric population. However, no geriatric-specific problems have been documented to date.\r\n\u003ch3\u003eBreastfeeding\u003c\/h3\u003e\r\nThere are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.\r\n\u003ch3\u003eDrug Interactions\u003c\/h3\u003e\r\nAlthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.\r\n\r\nUsing this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.\r\n\u003cul\u003e\r\n \t\u003cli\u003eAbametapir\u003c\/li\u003e\r\n \t\u003cli\u003eApalutamide\u003c\/li\u003e\r\n \t\u003cli\u003eBoceprevir\u003c\/li\u003e\r\n \t\u003cli\u003eCarbamazepine\u003c\/li\u003e\r\n \t\u003cli\u003eCeritinib\u003c\/li\u003e\r\n \t\u003cli\u003eClarithromycin\u003c\/li\u003e\r\n \t\u003cli\u003eCobicistat\u003c\/li\u003e\r\n \t\u003cli\u003eConivaptan\u003c\/li\u003e\r\n \t\u003cli\u003eEnzalutamide\u003c\/li\u003e\r\n \t\u003cli\u003eFedratinib\u003c\/li\u003e\r\n \t\u003cli\u003eFexinidazole\u003c\/li\u003e\r\n \t\u003cli\u003eFosnetupitant\u003c\/li\u003e\r\n \t\u003cli\u003eFosphenytoin\u003c\/li\u003e\r\n \t\u003cli\u003eIdelalisib\u003c\/li\u003e\r\n \t\u003cli\u003eIndinavir\u003c\/li\u003e\r\n \t\u003cli\u003eItraconazole\u003c\/li\u003e\r\n \t\u003cli\u003eKetoconazole\u003c\/li\u003e\r\n \t\u003cli\u003eLopinavir\u003c\/li\u003e\r\n \t\u003cli\u003eLumacaftor\u003c\/li\u003e\r\n \t\u003cli\u003eMitotane\u003c\/li\u003e\r\n \t\u003cli\u003eNefazodone\u003c\/li\u003e\r\n \t\u003cli\u003eNelfinavir\u003c\/li\u003e\r\n \t\u003cli\u003eNetupitant\u003c\/li\u003e\r\n \t\u003cli\u003ePhenytoin\u003c\/li\u003e\r\n \t\u003cli\u003ePosaconazole\u003c\/li\u003e\r\n \t\u003cli\u003eRifampin\u003c\/li\u003e\r\n \t\u003cli\u003eRitonavir\u003c\/li\u003e\r\n \t\u003cli\u003eSaquinavir\u003c\/li\u003e\r\n \t\u003cli\u003eSt John's Wort\u003c\/li\u003e\r\n \t\u003cli\u003eTelaprevir\u003c\/li\u003e\r\n \t\u003cli\u003eTelithromycin\u003c\/li\u003e\r\n \t\u003cli\u003eVoriconazole\u003c\/li\u003e\r\n \t\u003cli\u003eWarfarin\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eOther Interactions\u003c\/h3\u003e\r\nCertain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.\r\n\r\nUsing this medicine with any of the following is usually not recommended, but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrapefruit Juice\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eOther Medical Problems\u003c\/h3\u003e\r\nThe presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:\r\n\u003cul\u003e\r\n \t\u003cli\u003eBleeding problems or\u003c\/li\u003e\r\n \t\u003cli\u003eBlood clots or\u003c\/li\u003e\r\n \t\u003cli\u003eHeart attack, acute or\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension (high blood pressure), uncontrolled or\u003c\/li\u003e\r\n \t\u003cli\u003eHypocalcemia (low calcium levels in the blood) or\u003c\/li\u003e\r\n \t\u003cli\u003eHypothyroidism or\u003c\/li\u003e\r\n \t\u003cli\u003eProteinuria (protein in the urine) or\u003c\/li\u003e\r\n \t\u003cli\u003eStomach fistula or perforation (a hole in the stomach) or\u003c\/li\u003e\r\n \t\u003cli\u003eStroke, recent—Use with caution. May make these conditions worse.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDental or tooth problems or\u003c\/li\u003e\r\n \t\u003cli\u003eDental procedures or surgery or\u003c\/li\u003e\r\n \t\u003cli\u003ePoor oral hygiene or\u003c\/li\u003e\r\n \t\u003cli\u003eTooth infection—May increase risk for severe jaw problems.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eHematemesis (vomiting of blood), recent or\u003c\/li\u003e\r\n \t\u003cli\u003eHemoptysis (coughing up blood), recent or\u003c\/li\u003e\r\n \t\u003cli\u003eHemorrhage (severe bleeding), recent history or\u003c\/li\u003e\r\n \t\u003cli\u003eMelena (black, tarry stools)—Should not be used in patients with these conditions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eLiver disease, mild or moderate—Use with caution. The effects may be increased because of slower removal of the medicine from the body.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eLiver disease, severe—Use is not recommended in patients with these conditions.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eProper Use\u003c\/h2\u003e\r\nMedicines used to treat cancer are very strong and can have many side effects. Before taking this medicine, make sure you understand all the risks and benefits. It is important for you to work closely with your doctor during your treatment.\r\n\r\nTake this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. To do so may increase the chance of unwanted effects.\r\n\r\nThis medicine comes with a patient information insert. Read and follow the instructions carefully. Ask your doctor if you have any questions.\r\n\r\n\u003cstrong\u003e\u003cspan style=\"color: #ff0000;\"\u003eDo not substitute Cabonni \u003cspan style=\"color: #000000;\"\u003etablets\u003c\/span\u003e with cabozantinib \u003cspan style=\"color: #0000ff;\"\u003ecapsules\u003c\/span\u003e. Do not substitute Cabonni \u003cspan style=\"color: #0000ff;\"\u003ecapsules\u003c\/span\u003e with cabozantinib \u003cspan style=\"color: #000000;\"\u003etablets.\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\r\n\r\nTake this medicine on an empty stomach. Do not eat for at least 2 hours before and at least 1 hour after taking this medicine.\r\n\r\nSwallow the medicine whole with a full glass (at least 8 ounces) of water. Do not crush, break, chew, or open the capsule or tablet.\r\n\r\nDo not eat grapefruit or drink grapefruit juice while you are using this medicine. Grapefruit and grapefruit juice may increase the amount of this medicine in the blood.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch3\u003eDosing\u003c\/h3\u003e\r\nThe dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.\r\n\r\nThe amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor oral dosage form (capsules):\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor thyroid cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—140 milligrams (mg) (one 80 mg and three 20 mg capsules) per day as a single dose. Your doctor may adjust the dose as needed.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor oral dosage form (tablets):\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor advanced kidney cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—60 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor advanced kidney cancer in combination with nivolumab:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—40 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor hepatocellular carcinoma:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—60 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor thyroid cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults and children 12 years of age and older—Dose is based on body surface area (BSA) and must be determined by your doctor.\r\n\u003cul\u003e\r\n \t\u003cli\u003eBSA of 1.2 meter squared (m2) or more—60 milligrams (mg) once a day. Your doctor may adjust your dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eBSA of less than 1.2 m2—40 mg once a day. Your doctor may adjust your dose as needed and tolerated.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eChildren younger than 12 years of age—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eMissed Dose\u003c\/h3\u003e\r\nIf you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.\r\n\r\nIf you miss a dose of this medicine and it is less than 12 hours until your next scheduled dose, skip the missed dose and take your next dose at the normal time. If you miss a dose and it is more than 12 hours until your next dose, take it as soon as possible and take your next dose at the normal time.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch3\u003eStorage\u003c\/h3\u003e\r\nStore the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.\r\n\r\nKeep out of the reach of children.\r\n\r\nDo not keep outdated medicine or medicine no longer needed.\r\n\r\nAsk your healthcare professional how you should dispose of any medicine you do not use.\r\n\u003ch2\u003ePrecautions\u003c\/h2\u003e\r\nIt is very important that your doctor check your progress at regular visits to make sure this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.\r\n\r\nUsing this medicine while you are pregnant can harm your unborn baby. If you are a woman who can get pregnant, you doctor may do tests to make sure you are not pregnant before starting treatment. You should continue to use birth control during treatment with this medicine and for at least 4 months after the last dose to keep from getting pregnant. If you think you have become pregnant while using the medicine, tell your doctor right away.\r\n\r\nCheck with your doctor right away if you have severe stomach pain, gagging, coughing, or choking when you eat or drink. These could be symptoms of a perforation (tear) or fistula (hole) in the bowel.\r\n\r\nThis medicine may increase your risk of bleeding. Tell your doctor right away if you cough up blood or have bleeding gums, difficulty with breathing or swallowing, dizziness, increased menstrual flow or vaginal bleeding, nosebleeds, prolonged bleeding from cuts, red or dark brown urine, or red or black, tarry stools. Stay away from rough sports or other situations where you could be bruised, cut, or injured. Brush and floss your teeth gently. Be careful when using sharp objects, including razors and fingernail clippers.\r\n\r\nThis medicine may increase your risk of developing blood clots. Check with your doctor right away if you have swelling and pain in your arms, legs, or stomach, chest pain, difficulty with breathing, loss of sensation, confusion, or problems with muscle control or speech.\r\n\r\nCheck with your doctor right away if you have chest pain or discomfort, nausea, pain or discomfort in your arms, jaw, back, or neck, sweating, or vomiting. These could be symptoms of a heart attack.\r\n\r\nMake sure any doctor or dentist who treats you knows that you are using this medicine. You may need to stop using this medicine at least 3 weeks before having surgery, including dental procedures. Wait for at least 2 weeks after major surgery, or until adequate wound healing before taking this medicine again.\r\n\r\nYour doctor will check your blood pressure on a regular basis while you are using this medicine. You might need to monitor your blood pressure at home. Tell your doctor right away if you have a severe headache, lightheadedness, or changes in your vision.\r\n\r\nTell your doctor right away if you have jaw tightness, swelling, numbness, pain, or a loose tooth. This could be symptoms of a severe jaw problem.\r\n\r\nThis medicine may cause a serious skin problem called hand-foot syndrome or palmar plantar erythrodysesthesia syndrome. Check with your doctor if you have a rash that does not go away or redness, pain, swelling, or blisters on the palms of your hands or soles of your feet.\r\n\r\nCheck with your doctor right away if you have dark urine, clay-colored stools, stomach pain, or yellow eyes or skin. These may be symptoms of a serious liver problem.\r\n\r\nThis medicine may cause adrenal gland problems. Check with your doctor right away if you have darkening of the skin, diarrhea, dizziness, fainting, loss of appetite, mental depression, nausea, skin rash, unusual tiredness or weakness, or vomiting.\r\n\r\nCheck with your doctor right away if you have a headache, seizures, confusion, blurred vision or other visual problems. These may be symptoms of a rare and serious brain condition called reversible posterior leukoencephalopathy syndrome.\r\n\r\nThis medicine may cause hypocalcemia (low calcium in the blood). Check with your doctor right away if you have confusion, difficulty in breathing, irregular heartbeats, mood or mental changes, muscle cramps in the hands, arms, feet, or face, numbness and tingling around the mouth, fingertips, or feet, seizures, stomach cramps, tremor, or trouble breathing.\r\n\r\nTalk with your doctor before using this medicine if you plan to have children. Some men and women who use this medicine have become infertile (unable to have children).\r\n\r\nDo not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal (eg, St. John's wort) or vitamin supplements.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch2\u003eSide Effects\u003c\/h2\u003e\r\nAlong with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.\r\n\r\nCheck with your doctor immediately if any of the following side effects occur:\r\n\u003cdiv id=\"ad-mobile-top-container\"\u003e\u003c\/div\u003e\r\n\u003ch4\u003eMore common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBlurred vision\u003c\/li\u003e\r\n \t\u003cli\u003eburning, numbness, tingling, or painful sensations\u003c\/li\u003e\r\n \t\u003cli\u003econfusion\u003c\/li\u003e\r\n \t\u003cli\u003econstipation\u003c\/li\u003e\r\n \t\u003cli\u003edark urine\u003c\/li\u003e\r\n \t\u003cli\u003edarkening of the skin\u003c\/li\u003e\r\n \t\u003cli\u003edecreased urination\u003c\/li\u003e\r\n \t\u003cli\u003ediarrhea\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty with breathing or swallowing\u003c\/li\u003e\r\n \t\u003cli\u003edizziness\u003c\/li\u003e\r\n \t\u003cli\u003edry mouth\u003c\/li\u003e\r\n \t\u003cli\u003edry skin and hair\u003c\/li\u003e\r\n \t\u003cli\u003efainting\u003c\/li\u003e\r\n \t\u003cli\u003efeeling cold\u003c\/li\u003e\r\n \t\u003cli\u003ehair loss\u003c\/li\u003e\r\n \t\u003cli\u003eheadache\u003c\/li\u003e\r\n \t\u003cli\u003ehoarseness or husky voice\u003c\/li\u003e\r\n \t\u003cli\u003eincrease in heart rate\u003c\/li\u003e\r\n \t\u003cli\u003elightheadedness\u003c\/li\u003e\r\n \t\u003cli\u003eloss of appetite\u003c\/li\u003e\r\n \t\u003cli\u003emental depression\u003c\/li\u003e\r\n \t\u003cli\u003emuscle cramps, spasms, and stiffness\u003c\/li\u003e\r\n \t\u003cli\u003enausea or vomiting\u003c\/li\u003e\r\n \t\u003cli\u003enervousness\u003c\/li\u003e\r\n \t\u003cli\u003epain in the chest, groin, or legs, especially the calves\u003c\/li\u003e\r\n \t\u003cli\u003epounding in the ears\u003c\/li\u003e\r\n \t\u003cli\u003erapid breathing\u003c\/li\u003e\r\n \t\u003cli\u003eredness, swelling, or pain of the skin\u003c\/li\u003e\r\n \t\u003cli\u003escaling of the skin on the hands and feet\u003c\/li\u003e\r\n \t\u003cli\u003esevere, sudden headache\u003c\/li\u003e\r\n \t\u003cli\u003eskin rash or ulcers\u003c\/li\u003e\r\n \t\u003cli\u003eslow or fast heartbeat\u003c\/li\u003e\r\n \t\u003cli\u003eslurred speech\u003c\/li\u003e\r\n \t\u003cli\u003estomach pain\u003c\/li\u003e\r\n \t\u003cli\u003esudden loss of coordination\u003c\/li\u003e\r\n \t\u003cli\u003esudden, severe weakness or numbness in the arm or leg\u003c\/li\u003e\r\n \t\u003cli\u003esunken eyes\u003c\/li\u003e\r\n \t\u003cli\u003ethirst\u003c\/li\u003e\r\n \t\u003cli\u003eunsteadiness or awkwardness\u003c\/li\u003e\r\n \t\u003cli\u003eunusual tiredness or weakness\u003c\/li\u003e\r\n \t\u003cli\u003evision changes\u003c\/li\u003e\r\n \t\u003cli\u003eweakness in the arms, hands, legs, or feet\u003c\/li\u003e\r\n \t\u003cli\u003eweight gain\u003c\/li\u003e\r\n \t\u003cli\u003ewrinkled skin\u003c\/li\u003e\r\n \t\u003cli\u003eyellow eyes or skin\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003ch4\u003eLess common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBleeding gums\u003c\/li\u003e\r\n \t\u003cli\u003ebloody, black, or tarry stools\u003c\/li\u003e\r\n \t\u003cli\u003ecoughing up blood\u003c\/li\u003e\r\n \t\u003cli\u003eheartburn\u003c\/li\u003e\r\n \t\u003cli\u003eheavy jaw feeling\u003c\/li\u003e\r\n \t\u003cli\u003eincreased menstrual flow or vaginal bleeding\u003c\/li\u003e\r\n \t\u003cli\u003eindigestion\u003c\/li\u003e\r\n \t\u003cli\u003eloosening of a tooth\u003c\/li\u003e\r\n \t\u003cli\u003emood or mental changes\u003c\/li\u003e\r\n \t\u003cli\u003emuscle cramps in the hands, arms, feet, legs, or face\u003c\/li\u003e\r\n \t\u003cli\u003enosebleeds\u003c\/li\u003e\r\n \t\u003cli\u003enumbness and tingling around the mouth, fingertips, or feet\u003c\/li\u003e\r\n \t\u003cli\u003epain, swelling, or numbness in the mouth or jaw\u003c\/li\u003e\r\n \t\u003cli\u003eparalysis\u003c\/li\u003e\r\n \t\u003cli\u003eprolonged bleeding from cuts\u003c\/li\u003e\r\n \t\u003cli\u003ered or dark brown urine\u003c\/li\u003e\r\n \t\u003cli\u003eseizures\u003c\/li\u003e\r\n \t\u003cli\u003esevere stomach pain, cramping, or burning\u003c\/li\u003e\r\n \t\u003cli\u003etremor\u003c\/li\u003e\r\n \t\u003cli\u003etrouble breathing\u003c\/li\u003e\r\n \t\u003cli\u003evomiting of material that looks like coffee grounds, severe and continuing\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003ch4\u003eRare\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eDisturbed color perception\u003c\/li\u003e\r\n \t\u003cli\u003edouble vision\u003c\/li\u003e\r\n \t\u003cli\u003ehalos around lights\u003c\/li\u003e\r\n \t\u003cli\u003enight blindness\u003c\/li\u003e\r\n \t\u003cli\u003eoverbright appearance of lights\u003c\/li\u003e\r\n \t\u003cli\u003etunnel vision\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\nSome side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:\r\n\u003ch4\u003eMore common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBelching\u003c\/li\u003e\r\n \t\u003cli\u003ebleeding after defecation\u003c\/li\u003e\r\n \t\u003cli\u003echange in taste\u003c\/li\u003e\r\n \t\u003cli\u003echanges in hair color\u003c\/li\u003e\r\n \t\u003cli\u003edecreased appetite\u003c\/li\u003e\r\n \t\u003cli\u003edecreased weight\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty having a bowel movement\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty with moving\u003c\/li\u003e\r\n \t\u003cli\u003efear\u003c\/li\u003e\r\n \t\u003cli\u003elack or loss of strength\u003c\/li\u003e\r\n \t\u003cli\u003eloss of taste\u003c\/li\u003e\r\n \t\u003cli\u003emuscle pain\u003c\/li\u003e\r\n \t\u003cli\u003epain in the joints\u003c\/li\u003e\r\n \t\u003cli\u003erash\u003c\/li\u003e\r\n \t\u003cli\u003esore throat\u003c\/li\u003e\r\n \t\u003cli\u003estomach discomfort, upset, or pain\u003c\/li\u003e\r\n \t\u003cli\u003eswelling or inflammation of the mouth\u003c\/li\u003e\r\n \t\u003cli\u003euncomfortable swelling around the anus\u003c\/li\u003e\r\n \t\u003cli\u003evoice changes\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003c\/div\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947150379,"sku":"RL1420230901445","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1950.jpg?v=1787022087"},{"product_id":"cabonni-cabozantinib-80mg-2","title":"Cabonni 80 (Cabozantinib)","description":"\u003cdiv class=\"page-header\"\u003e\r\n\u003cdiv class=\"headers v2 lg\"\u003e\r\n\r\n\u003cstrong\u003eGeneric Name: Cabozantinib\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eBrand Names: Cabonni (Cabozantinib) 80mg.\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eDosage form:\u003c\/strong\u003e 80mg x 30Capsules.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv id=\"main-content\" role=\"main\"\u003e\r\n\u003ch2\u003eDescription\u003c\/h2\u003e\r\n\u003cstrong\u003eCabonni (Cabozantinib) \u003c\/strong\u003ecapsule is used to treat medullary thyroid cancer that has already spread to different parts of the body.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is used alone to treat advanced kidney cancer. It is also used in combination with nivolumab as first-line treatment for advanced kidney cancer.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is also used to treat a type of liver cancer, called hepatocellular carcinoma, in patients who have been previously treated with other medicines (eg, sorafenib).\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablet is also used to treat differentiated thyroid cancer that has already spread to different parts of the body, in patients who can no longer be treated with radioactive iodine or not able to receive radioactive iodine, and have been previously treated with other medicines (eg, VEGFR-targeted treatment) but did not work well.\r\n\r\n\u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e is an antineoplastic (cancer) medicine. It interferes with the growth of cancer cells, which are eventually destroyed by the body.\r\n\r\nThis medicine is available only with your doctor's prescription.\r\n\r\nThis product is available in the following dosage forms:\r\n\u003cul\u003e\r\n \t\u003cli\u003eCapsule\u003c\/li\u003e\r\n \t\u003cli\u003eTablet\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eBefore Using\u003c\/h2\u003e\r\nIn deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:\r\n\u003ch3\u003eAllergies\u003c\/h3\u003e\r\nTell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.\r\n\u003ch3\u003ePediatric\u003c\/h3\u003e\r\nAppropriate studies have not been performed on the relationship of age to the effects of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e in children younger than 12 years of age to treat differentiated thyroid cancer or in children to treat medullary thyroid cancer, liver cancer, and advanced kidney cancer. Safety and efficacy have not been established.\r\n\u003ch3\u003eGeriatric\u003c\/h3\u003e\r\nAppropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e tablets in the elderly.\r\n\r\nAppropriate studies have not been performed on the relationship of age to the effects of \u003cstrong\u003eCabonni (Cabozantinib)\u003c\/strong\u003e capsules in the geriatric population. However, no geriatric-specific problems have been documented to date.\r\n\u003ch3\u003eBreastfeeding\u003c\/h3\u003e\r\nThere are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.\r\n\u003ch3\u003eDrug Interactions\u003c\/h3\u003e\r\nAlthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.\r\n\r\nUsing this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.\r\n\u003cul\u003e\r\n \t\u003cli\u003eAbametapir\u003c\/li\u003e\r\n \t\u003cli\u003eApalutamide\u003c\/li\u003e\r\n \t\u003cli\u003eBoceprevir\u003c\/li\u003e\r\n \t\u003cli\u003eCarbamazepine\u003c\/li\u003e\r\n \t\u003cli\u003eCeritinib\u003c\/li\u003e\r\n \t\u003cli\u003eClarithromycin\u003c\/li\u003e\r\n \t\u003cli\u003eCobicistat\u003c\/li\u003e\r\n \t\u003cli\u003eConivaptan\u003c\/li\u003e\r\n \t\u003cli\u003eEnzalutamide\u003c\/li\u003e\r\n \t\u003cli\u003eFedratinib\u003c\/li\u003e\r\n \t\u003cli\u003eFexinidazole\u003c\/li\u003e\r\n \t\u003cli\u003eFosnetupitant\u003c\/li\u003e\r\n \t\u003cli\u003eFosphenytoin\u003c\/li\u003e\r\n \t\u003cli\u003eIdelalisib\u003c\/li\u003e\r\n \t\u003cli\u003eIndinavir\u003c\/li\u003e\r\n \t\u003cli\u003eItraconazole\u003c\/li\u003e\r\n \t\u003cli\u003eKetoconazole\u003c\/li\u003e\r\n \t\u003cli\u003eLopinavir\u003c\/li\u003e\r\n \t\u003cli\u003eLumacaftor\u003c\/li\u003e\r\n \t\u003cli\u003eMitotane\u003c\/li\u003e\r\n \t\u003cli\u003eNefazodone\u003c\/li\u003e\r\n \t\u003cli\u003eNelfinavir\u003c\/li\u003e\r\n \t\u003cli\u003eNetupitant\u003c\/li\u003e\r\n \t\u003cli\u003ePhenytoin\u003c\/li\u003e\r\n \t\u003cli\u003ePosaconazole\u003c\/li\u003e\r\n \t\u003cli\u003eRifampin\u003c\/li\u003e\r\n \t\u003cli\u003eRitonavir\u003c\/li\u003e\r\n \t\u003cli\u003eSaquinavir\u003c\/li\u003e\r\n \t\u003cli\u003eSt John's Wort\u003c\/li\u003e\r\n \t\u003cli\u003eTelaprevir\u003c\/li\u003e\r\n \t\u003cli\u003eTelithromycin\u003c\/li\u003e\r\n \t\u003cli\u003eVoriconazole\u003c\/li\u003e\r\n \t\u003cli\u003eWarfarin\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eOther Interactions\u003c\/h3\u003e\r\nCertain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.\r\n\r\nUsing this medicine with any of the following is usually not recommended, but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrapefruit Juice\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eOther Medical Problems\u003c\/h3\u003e\r\nThe presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:\r\n\u003cul\u003e\r\n \t\u003cli\u003eBleeding problems or\u003c\/li\u003e\r\n \t\u003cli\u003eBlood clots or\u003c\/li\u003e\r\n \t\u003cli\u003eHeart attack, acute or\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension (high blood pressure), uncontrolled or\u003c\/li\u003e\r\n \t\u003cli\u003eHypocalcemia (low calcium levels in the blood) or\u003c\/li\u003e\r\n \t\u003cli\u003eHypothyroidism or\u003c\/li\u003e\r\n \t\u003cli\u003eProteinuria (protein in the urine) or\u003c\/li\u003e\r\n \t\u003cli\u003eStomach fistula or perforation (a hole in the stomach) or\u003c\/li\u003e\r\n \t\u003cli\u003eStroke, recent—Use with caution. May make these conditions worse.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDental or tooth problems or\u003c\/li\u003e\r\n \t\u003cli\u003eDental procedures or surgery or\u003c\/li\u003e\r\n \t\u003cli\u003ePoor oral hygiene or\u003c\/li\u003e\r\n \t\u003cli\u003eTooth infection—May increase risk for severe jaw problems.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eHematemesis (vomiting of blood), recent or\u003c\/li\u003e\r\n \t\u003cli\u003eHemoptysis (coughing up blood), recent or\u003c\/li\u003e\r\n \t\u003cli\u003eHemorrhage (severe bleeding), recent history or\u003c\/li\u003e\r\n \t\u003cli\u003eMelena (black, tarry stools)—Should not be used in patients with these conditions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eLiver disease, mild or moderate—Use with caution. The effects may be increased because of slower removal of the medicine from the body.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eLiver disease, severe—Use is not recommended in patients with these conditions.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eProper Use\u003c\/h2\u003e\r\nMedicines used to treat cancer are very strong and can have many side effects. Before taking this medicine, make sure you understand all the risks and benefits. It is important for you to work closely with your doctor during your treatment.\r\n\r\nTake this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. To do so may increase the chance of unwanted effects.\r\n\r\nThis medicine comes with a patient information insert. Read and follow the instructions carefully. Ask your doctor if you have any questions.\r\n\r\n\u003cstrong\u003eDo not substitute Cabonni tablets with cabozantinib capsules. Do not substitute Cabonni capsules with cabozantinib tablets.\u003c\/strong\u003e\r\n\r\nTake this medicine on an empty stomach. Do not eat for at least 2 hours before and at least 1 hour after taking this medicine.\r\n\r\nSwallow the medicine whole with a full glass (at least 8 ounces) of water. Do not crush, break, chew, or open the capsule or tablet.\r\n\r\nDo not eat grapefruit or drink grapefruit juice while you are using this medicine. Grapefruit and grapefruit juice may increase the amount of this medicine in the blood.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch3\u003eDosing\u003c\/h3\u003e\r\nThe dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.\r\n\r\nThe amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor oral dosage form (capsules):\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor thyroid cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—140 milligrams (mg) (one 80 mg and three 20 mg capsules) per day as a single dose. Your doctor may adjust the dose as needed.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor oral dosage form (tablets):\r\n\u003cul\u003e\r\n \t\u003cli\u003eFor advanced kidney cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—60 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor advanced kidney cancer in combination with nivolumab:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—40 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor hepatocellular carcinoma:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults—60 milligrams (mg) once a day. Your doctor may adjust the dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eChildren—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eFor thyroid cancer:\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdults and children 12 years of age and older—Dose is based on body surface area (BSA) and must be determined by your doctor.\r\n\u003cul\u003e\r\n \t\u003cli\u003eBSA of 1.2 meter squared (m2) or more—60 milligrams (mg) once a day. Your doctor may adjust your dose as needed and tolerated.\u003c\/li\u003e\r\n \t\u003cli\u003eBSA of less than 1.2 m2—40 mg once a day. Your doctor may adjust your dose as needed and tolerated.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003eChildren younger than 12 years of age—Use and dose must be determined by your doctor.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eMissed Dose\u003c\/h3\u003e\r\nIf you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.\r\n\r\nIf you miss a dose of this medicine and it is less than 12 hours until your next scheduled dose, skip the missed dose and take your next dose at the normal time. If you miss a dose and it is more than 12 hours until your next dose, take it as soon as possible and take your next dose at the normal time.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch3\u003eStorage\u003c\/h3\u003e\r\nStore the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.\r\n\r\nKeep out of the reach of children.\r\n\r\nDo not keep outdated medicine or medicine no longer needed.\r\n\r\nAsk your healthcare professional how you should dispose of any medicine you do not use.\r\n\u003ch2\u003ePrecautions\u003c\/h2\u003e\r\nIt is very important that your doctor check your progress at regular visits to make sure this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.\r\n\r\nUsing this medicine while you are pregnant can harm your unborn baby. If you are a woman who can get pregnant, you doctor may do tests to make sure you are not pregnant before starting treatment. You should continue to use birth control during treatment with this medicine and for at least 4 months after the last dose to keep from getting pregnant. If you think you have become pregnant while using the medicine, tell your doctor right away.\r\n\r\nCheck with your doctor right away if you have severe stomach pain, gagging, coughing, or choking when you eat or drink. These could be symptoms of a perforation (tear) or fistula (hole) in the bowel.\r\n\r\nThis medicine may increase your risk of bleeding. Tell your doctor right away if you cough up blood or have bleeding gums, difficulty with breathing or swallowing, dizziness, increased menstrual flow or vaginal bleeding, nosebleeds, prolonged bleeding from cuts, red or dark brown urine, or red or black, tarry stools. Stay away from rough sports or other situations where you could be bruised, cut, or injured. Brush and floss your teeth gently. Be careful when using sharp objects, including razors and fingernail clippers.\r\n\r\nThis medicine may increase your risk of developing blood clots. Check with your doctor right away if you have swelling and pain in your arms, legs, or stomach, chest pain, difficulty with breathing, loss of sensation, confusion, or problems with muscle control or speech.\r\n\r\nCheck with your doctor right away if you have chest pain or discomfort, nausea, pain or discomfort in your arms, jaw, back, or neck, sweating, or vomiting. These could be symptoms of a heart attack.\r\n\r\nMake sure any doctor or dentist who treats you knows that you are using this medicine. You may need to stop using this medicine at least 3 weeks before having surgery, including dental procedures. Wait for at least 2 weeks after major surgery, or until adequate wound healing before taking this medicine again.\r\n\r\nYour doctor will check your blood pressure on a regular basis while you are using this medicine. You might need to monitor your blood pressure at home. Tell your doctor right away if you have a severe headache, lightheadedness, or changes in your vision.\r\n\r\nTell your doctor right away if you have jaw tightness, swelling, numbness, pain, or a loose tooth. This could be symptoms of a severe jaw problem.\r\n\r\nThis medicine may cause a serious skin problem called hand-foot syndrome or palmar plantar erythrodysesthesia syndrome. Check with your doctor if you have a rash that does not go away or redness, pain, swelling, or blisters on the palms of your hands or soles of your feet.\r\n\r\nCheck with your doctor right away if you have dark urine, clay-colored stools, stomach pain, or yellow eyes or skin. These may be symptoms of a serious liver problem.\r\n\r\nThis medicine may cause adrenal gland problems. Check with your doctor right away if you have darkening of the skin, diarrhea, dizziness, fainting, loss of appetite, mental depression, nausea, skin rash, unusual tiredness or weakness, or vomiting.\r\n\r\nCheck with your doctor right away if you have a headache, seizures, confusion, blurred vision or other visual problems. These may be symptoms of a rare and serious brain condition called reversible posterior leukoencephalopathy syndrome.\r\n\r\nThis medicine may cause hypocalcemia (low calcium in the blood). Check with your doctor right away if you have confusion, difficulty in breathing, irregular heartbeats, mood or mental changes, muscle cramps in the hands, arms, feet, or face, numbness and tingling around the mouth, fingertips, or feet, seizures, stomach cramps, tremor, or trouble breathing.\r\n\r\nTalk with your doctor before using this medicine if you plan to have children. Some men and women who use this medicine have become infertile (unable to have children).\r\n\r\nDo not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal (eg, St. John's wort) or vitamin supplements.\r\n\r\n\u003chr\u003e\r\n\r\n\u003ch2\u003eSide Effects\u003c\/h2\u003e\r\nAlong with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.\r\n\r\nCheck with your doctor immediately if any of the following side effects occur:\r\n\u003cdiv id=\"ad-mobile-top-container\"\u003e\u003c\/div\u003e\r\n\u003ch4\u003eMore common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBlurred vision\u003c\/li\u003e\r\n \t\u003cli\u003eburning, numbness, tingling, or painful sensations\u003c\/li\u003e\r\n \t\u003cli\u003econfusion\u003c\/li\u003e\r\n \t\u003cli\u003econstipation\u003c\/li\u003e\r\n \t\u003cli\u003edark urine\u003c\/li\u003e\r\n \t\u003cli\u003edarkening of the skin\u003c\/li\u003e\r\n \t\u003cli\u003edecreased urination\u003c\/li\u003e\r\n \t\u003cli\u003ediarrhea\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty with breathing or swallowing\u003c\/li\u003e\r\n \t\u003cli\u003edizziness\u003c\/li\u003e\r\n \t\u003cli\u003edry mouth\u003c\/li\u003e\r\n \t\u003cli\u003edry skin and hair\u003c\/li\u003e\r\n \t\u003cli\u003efainting\u003c\/li\u003e\r\n \t\u003cli\u003efeeling cold\u003c\/li\u003e\r\n \t\u003cli\u003ehair loss\u003c\/li\u003e\r\n \t\u003cli\u003eheadache\u003c\/li\u003e\r\n \t\u003cli\u003ehoarseness or husky voice\u003c\/li\u003e\r\n \t\u003cli\u003eincrease in heart rate\u003c\/li\u003e\r\n \t\u003cli\u003elightheadedness\u003c\/li\u003e\r\n \t\u003cli\u003eloss of appetite\u003c\/li\u003e\r\n \t\u003cli\u003emental depression\u003c\/li\u003e\r\n \t\u003cli\u003emuscle cramps, spasms, and stiffness\u003c\/li\u003e\r\n \t\u003cli\u003enausea or vomiting\u003c\/li\u003e\r\n \t\u003cli\u003enervousness\u003c\/li\u003e\r\n \t\u003cli\u003epain in the chest, groin, or legs, especially the calves\u003c\/li\u003e\r\n \t\u003cli\u003epounding in the ears\u003c\/li\u003e\r\n \t\u003cli\u003erapid breathing\u003c\/li\u003e\r\n \t\u003cli\u003eredness, swelling, or pain of the skin\u003c\/li\u003e\r\n \t\u003cli\u003escaling of the skin on the hands and feet\u003c\/li\u003e\r\n \t\u003cli\u003esevere, sudden headache\u003c\/li\u003e\r\n \t\u003cli\u003eskin rash or ulcers\u003c\/li\u003e\r\n \t\u003cli\u003eslow or fast heartbeat\u003c\/li\u003e\r\n \t\u003cli\u003eslurred speech\u003c\/li\u003e\r\n \t\u003cli\u003estomach pain\u003c\/li\u003e\r\n \t\u003cli\u003esudden loss of coordination\u003c\/li\u003e\r\n \t\u003cli\u003esudden, severe weakness or numbness in the arm or leg\u003c\/li\u003e\r\n \t\u003cli\u003esunken eyes\u003c\/li\u003e\r\n \t\u003cli\u003ethirst\u003c\/li\u003e\r\n \t\u003cli\u003eunsteadiness or awkwardness\u003c\/li\u003e\r\n \t\u003cli\u003eunusual tiredness or weakness\u003c\/li\u003e\r\n \t\u003cli\u003evision changes\u003c\/li\u003e\r\n \t\u003cli\u003eweakness in the arms, hands, legs, or feet\u003c\/li\u003e\r\n \t\u003cli\u003eweight gain\u003c\/li\u003e\r\n \t\u003cli\u003ewrinkled skin\u003c\/li\u003e\r\n \t\u003cli\u003eyellow eyes or skin\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003ch4\u003eLess common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBleeding gums\u003c\/li\u003e\r\n \t\u003cli\u003ebloody, black, or tarry stools\u003c\/li\u003e\r\n \t\u003cli\u003ecoughing up blood\u003c\/li\u003e\r\n \t\u003cli\u003eheartburn\u003c\/li\u003e\r\n \t\u003cli\u003eheavy jaw feeling\u003c\/li\u003e\r\n \t\u003cli\u003eincreased menstrual flow or vaginal bleeding\u003c\/li\u003e\r\n \t\u003cli\u003eindigestion\u003c\/li\u003e\r\n \t\u003cli\u003eloosening of a tooth\u003c\/li\u003e\r\n \t\u003cli\u003emood or mental changes\u003c\/li\u003e\r\n \t\u003cli\u003emuscle cramps in the hands, arms, feet, legs, or face\u003c\/li\u003e\r\n \t\u003cli\u003enosebleeds\u003c\/li\u003e\r\n \t\u003cli\u003enumbness and tingling around the mouth, fingertips, or feet\u003c\/li\u003e\r\n \t\u003cli\u003epain, swelling, or numbness in the mouth or jaw\u003c\/li\u003e\r\n \t\u003cli\u003eparalysis\u003c\/li\u003e\r\n \t\u003cli\u003eprolonged bleeding from cuts\u003c\/li\u003e\r\n \t\u003cli\u003ered or dark brown urine\u003c\/li\u003e\r\n \t\u003cli\u003eseizures\u003c\/li\u003e\r\n \t\u003cli\u003esevere stomach pain, cramping, or burning\u003c\/li\u003e\r\n \t\u003cli\u003etremor\u003c\/li\u003e\r\n \t\u003cli\u003etrouble breathing\u003c\/li\u003e\r\n \t\u003cli\u003evomiting of material that looks like coffee grounds, severe and continuing\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003ch4\u003eRare\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eDisturbed color perception\u003c\/li\u003e\r\n \t\u003cli\u003edouble vision\u003c\/li\u003e\r\n \t\u003cli\u003ehalos around lights\u003c\/li\u003e\r\n \t\u003cli\u003enight blindness\u003c\/li\u003e\r\n \t\u003cli\u003eoverbright appearance of lights\u003c\/li\u003e\r\n \t\u003cli\u003etunnel vision\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\nSome side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:\r\n\u003ch4\u003eMore common\u003c\/h4\u003e\r\n\u003col class=\"bullet\"\u003e\r\n \t\u003cli\u003eBelching\u003c\/li\u003e\r\n \t\u003cli\u003ebleeding after defecation\u003c\/li\u003e\r\n \t\u003cli\u003echange in taste\u003c\/li\u003e\r\n \t\u003cli\u003echanges in hair color\u003c\/li\u003e\r\n \t\u003cli\u003edecreased appetite\u003c\/li\u003e\r\n \t\u003cli\u003edecreased weight\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty having a bowel movement\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty with moving\u003c\/li\u003e\r\n \t\u003cli\u003efear\u003c\/li\u003e\r\n \t\u003cli\u003elack or loss of strength\u003c\/li\u003e\r\n \t\u003cli\u003eloss of taste\u003c\/li\u003e\r\n \t\u003cli\u003emuscle pain\u003c\/li\u003e\r\n \t\u003cli\u003epain in the joints\u003c\/li\u003e\r\n \t\u003cli\u003erash\u003c\/li\u003e\r\n \t\u003cli\u003esore throat\u003c\/li\u003e\r\n \t\u003cli\u003estomach discomfort, upset, or pain\u003c\/li\u003e\r\n \t\u003cli\u003eswelling or inflammation of the mouth\u003c\/li\u003e\r\n \t\u003cli\u003euncomfortable swelling around the anus\u003c\/li\u003e\r\n \t\u003cli\u003evoice changes\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003c\/div\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947445291,"sku":"RL1420230901327","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1950_2f7a4c3b-48d4-48ea-af1a-6a04b2c908b4.jpg?v=1787022094"},{"product_id":"reganni-regorafenib-2","title":"Reganni (Regorafenib)","description":"\u003cp\u003eRegorafenib, sold under the brand name Reganni,Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had two US approvals for advanced cancers.\u003c\/p\u003e\n\n\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003e\nRegorafenib is used to treat colon and rectal cancer (cancer that begins in the large intestine or the rectum) that has spread to other parts of the body in people who have not been treated successfully with certain other medications. It is also used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine [bowel], or esophagus [tube that connects the throat with the stomach]) in people who were not treated successfully with certain other medications. Regorafenib is also used to treat hepatocellular carcinoma (HCC; a type of liver cancer) in people who were previously treated with sorafenib (Nexafar). Regorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps to slow or stop the spread of cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eHow should this medicine be used?\u003cbr\u003e\nRegorafenib comes as a tablet to take by mouth. It is usually taken with a low-fat meal (containing under 600 calories and less than 30% of calories from fat) once a day for 3 weeks and then skipped for 1 week. This treatment period is called a cycle, and the cycle may be repeated for as long as your doctor recommends. Take regorafenib at the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take regorafenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\n\n\u003cp\u003eSwallow the tablets whole; do not split, chew, or crush them.\u003c\/p\u003e\n\n\u003cp\u003eYour doctor may decrease your dose of regorafenib or tell you to stop taking regorafenib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Continue to take regorafenib even if you feel well. Do not stop taking regorafenib without talking to your doctor.\u003c\/p\u003e\n\n\u003cp\u003eRegorafenib is not available at retail pharmacies. Your medication will be mailed to you or to your doctor from a specialty pharmacy. Ask your doctor if you have any questions about how you will receive your medication.\u003c\/p\u003e\n\n\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\n\n\u003cp\u003eOther uses for this medicine\u003cbr\u003e\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e\n\n\u003cp\u003eWhat side effects can this medication cause?\u003cbr\u003e\nRegorafenib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003cbr\u003e\ntiredness\u003cbr\u003e\nweakness\u003cbr\u003e\nloss of appetite\u003cbr\u003e\ndiarrhea\u003cbr\u003e\nswelling, pain, and redness of the lining of your mouth or throat\u003cbr\u003e\nweight loss\u003cbr\u003e\nhoarseness or other change in the sound of your voice.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947707435,"sku":"RL1420230901152","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663233650-af7da95e0ba5ff3.png?v=1787022100"},{"product_id":"mytanne-mitotane-2","title":"Mytanne (Mitotane)","description":"\u003cp\u003eMitotane, sold under the brand name Mytanne, Lysodren, is a steroidogenesis inhibitor and cytostatic antineoplastic medication which is used in the treatment of adrenocortical carcinoma and Cushing's syndrome. It is a derivative of the early insecticide DDT and an isomer of p,p'-DDD (4,4'-dichlorodiphenyldichloroethane) and is also known as 2,4'-(dichlorodiphenyl)-2,2-dichloroethane (o,p'-DDD).\u003c\/p\u003e\u003cp\u003eMedical uses\u003cbr\u003eMitotane has been produced by Bristol Myers Squibb but it is marketed as an orphan drug for adrenocortical carcinoma due to the small number of patients in need of it. Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease. In a 2007 retrospective study of 177 patients from 1985 to 2005 showed a significant increase in the recurrence-free interval after radical surgery followed by mitotane when compared to surgery alone. The drug is also sometimes used in the treatment of Cushing's syndrome.\u003c\/p\u003e\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003eMitotane is used to treat cancer of the adrenal gland that can not be treated with surgery. Mitotane is in a class of medications called antineoplastic agents. It works by slowing growth or reducing the size of the tumor.\u003c\/p\u003e\u003cp\u003eHow should this medicine be used?\u003cbr\u003eMitotane comes as a tablet to take by mouth. It is usually taken three to four times a day. Take mitotane at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take mitotane exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\u003cp\u003eYou will probably be hospitalized when you begin your treatment with mitotane. Your doctor will start you on a low dose of mitotane and gradually increase your dose.\u003c\/p\u003e\u003cp\u003eContinue to take mitotane even if you feel well. Do not stop taking mitotane without talking to your doctor.\u003c\/p\u003e\u003cp\u003eOther uses for this medicine\u003cbr\u003eMitotane is also sometimes used to treat Cushing's Syndrome (condition where the body produces too much of the hormone cortisol). Talk to your doctor about the risks of using this drug for your condition.\u003c\/p\u003e\u003cp\u003eThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e\u003cp\u003eWhat side effects can this medication cause?\u003cbr\u003eMitotane may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003cbr\u003eloss of appetite\u003cbr\u003enausea\u003cbr\u003evomiting\u003cbr\u003ediarrhea\u003cbr\u003edepression\u003cbr\u003elack of energy\u003cbr\u003eunusual drowsiness\u003cbr\u003efeeling that the room is spinning\u003cbr\u003echanges in vision\u003cbr\u003erash or changes in skin color.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947936811,"sku":"RL1420230901785","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663301895-0e615ccb35bc2db.jpg?v=1787022105"},{"product_id":"soranni-sorafenib-200mg-2","title":"Soranni (Sorafenib)","description":"\u003cstrong\u003eIndications\u003c\/strong\u003e\r\n\r\nIncluding: unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and local recovery that is refractory to radioactive iodine therapy\r\n\r\nHair or metastasis, and advanced differentiated thyroid cancer.\r\n\r\n\u003cstrong\u003eDose and administration method\u003c\/strong\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eMethod of administration\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e400mg (2 tablets) orally, twice a day, on an empty stomach.\u003c\/li\u003e\r\n \t\u003cli\u003eTo deal with suspected adverse drug reactions, treatment may need to be interrupted and\/or dose reduced. The dose can be reduced To 400mg once a day or to 400mg, once every other day.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"2\"\u003e\r\n \t\u003cli\u003eDosage specifications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTablets, 200mg.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"3\"\u003e\r\n \t\u003cli\u003eContraindications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePeople who are known to be allergic to sorafenib or any other components of the drug should not use sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eIn patients with squamous cell lung cancer, sorafenib is contraindicated in combination with carboplatin and paclitaxel.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eWarnings and Precautions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMyocardial ischemia and\/or infarction: consider temporarily or permanently discontinuing sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eBleeding: If bleeding requires medical intervention, consider discontinuing sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension: 6 weeks before treatment, regularly monitor blood pressure every week. Follow-up treatment should also be monitored regularly.\u003c\/li\u003e\r\n \t\u003cli\u003eSkin toxicity: Interrupt and\/or reduce the dose. Severe or persistent skin toxicity, or pregnant Stop taking the medication when you suspect Stevens-John syndrome and toxic epidermal necrolysis.\u003c\/li\u003e\r\n \t\u003cli\u003eGastrointestinal perforation: stop taking sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eProlonged QT interval: Patients with high risk of ventricular arrhythmia regularly monitor ECG and electrolyte levels.\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-induced hepatotoxicity: monitor liver function regularly; stop if there is an unexplained rise in transaminase Stop taking medicine.\u003c\/li\u003e\r\n \t\u003cli\u003eEmbryo toxicity: It is recommended that women of childbearing age avoid pregnancy when taking the drug.\u003c\/li\u003e\r\n \t\u003cli\u003eThyroid-stimulating hormone (TSH) damage in differentiated thyroid cancer (DTC): monitor TSH once a month,\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n(Please read this notice carefully and take the medicine according to this notice or under the guidance of a doctor)\r\n\u003cul\u003e\r\n \t\u003cli\u003eThyroid replacement therapy is suitable for patients with thyroid cancer.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAdverse reactions\u003c\/strong\u003e\r\n\r\nThe most common adverse reactions related to sorafenib (≥20%): diarrhea, fatigue, infection, baldness, Hand and foot skin reactions, rash, weight loss, anorexia, nausea, gastrointestinal pain and abdominal pain, high blood pressure and blood.\r\n\r\n\u003cstrong\u003estorage method\u003c\/strong\u003e\r\n\r\nShading, cool and dry place","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948493867,"sku":"RL1420230901102","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655894917-557e1a1ef535bfa.png?v=1787022116"},{"product_id":"generic-crizotinib-lucicriz","title":"LENVIDX-4 (Lenvatinib)","description":"\u003ch3\u003eAbout Lenvatinib\u003c\/h3\u003e\u003cp\u003eLenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\u003c\/p\u003e\u003cp\u003e24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_everolimus\"\u003eCombination therapy with everolimus\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\n\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\n\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_pembrolizumab\"\u003eCombination therapy with pembrolizumab\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\n\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\n\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Dose_based_on_actual_body_weight\"\u003eDose based on actual body weight\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Endometrial_Cancer\"\u003eEndometrial Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\u003c\/p\u003e\u003cp\u003e20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to pembrolizumab prescribing information for recommended dosing information\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"DTC_dose_reductions\"\u003eDTC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"RCC_or_endometrial_carcinoma_dose_reductions\"\u003eRCC or endometrial carcinoma dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_everolimus_in_RCC\"\u003eDose modification of everolimus in RCC\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\n\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_pembrolizumab_in_endometrial_carcinoma\"\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\n\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\n\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"HCC_dose_reductions\"\u003eHCC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"First_occurrence\"\u003eFirst occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Second_occurrence\"\u003eSecond occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Third_occurrence\"\u003eThird occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hypertension\"\u003eHypertension\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Cardiac_dysfunction\"\u003eCardiac dysfunction\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Arterial_thrombotic_event\"\u003eArterial thrombotic event\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Proteinuria\"\u003eProteinuria\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"GI_toxicity\"\u003eGI toxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_failure_or_impairment\"\u003eRenal failure or impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Reversible_posterior_leukoencephalopathy_syndrome_RPLS\"\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_CrCl_30_mLmin\"\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_Child-Pugh_C\"\u003eSevere (Child-Pugh C)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949902891,"sku":"RL3020241018","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-0942-jpg.webp?v=1787022139"},{"product_id":"generic-fionernone-lucifine","title":"LENVIDX-10 (Lenvatinib)","description":"\u003ch3\u003e\u003cspan id=\"About_Lenvatinib\"\u003eAbout Lenvatinib\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eLenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\u003c\/p\u003e\u003cp\u003e24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_everolimus\"\u003eCombination therapy with everolimus\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\n\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\n\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Combination_therapy_with_pembrolizumab\"\u003eCombination therapy with pembrolizumab\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\n\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\n\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Dose_based_on_actual_body_weight\"\u003eDose based on actual body weight\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Endometrial_Cancer\"\u003eEndometrial Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\u003c\/p\u003e\u003cp\u003e20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eRefer to pembrolizumab prescribing information for recommended dosing information\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"DTC_dose_reductions\"\u003eDTC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"RCC_or_endometrial_carcinoma_dose_reductions\"\u003eRCC or endometrial carcinoma dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_everolimus_in_RCC\"\u003eDose modification of everolimus in RCC\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\n\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Dose_modification_of_pembrolizumab_in_endometrial_carcinoma\"\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\n\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\n\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"HCC_dose_reductions\"\u003eHCC dose reductions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"First_occurrence\"\u003eFirst occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Second_occurrence\"\u003eSecond occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Third_occurrence\"\u003eThird occurrence\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\n\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hypertension\"\u003eHypertension\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Cardiac_dysfunction\"\u003eCardiac dysfunction\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Arterial_thrombotic_event\"\u003eArterial thrombotic event\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\n\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Proteinuria\"\u003eProteinuria\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"GI_toxicity\"\u003eGI toxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_failure_or_impairment\"\u003eRenal failure or impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Reversible_posterior_leukoencephalopathy_syndrome_RPLS\"\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_CrCl_30_mLmin\"\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Severe_Child-Pugh_C\"\u003eSevere (Child-Pugh C)\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949968427,"sku":"RL3020241018","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-0972-jpg.webp?v=1787022141"},{"product_id":"generic-mitotane-mitodx","title":"MITODX (Mitotane)","description":"\u003cp\u003eMitotane is a steroidogenesis inhibitor and cytostatic antineoplastic medication which is used in the treatment of adrenocortical carcinoma and Cushing's syndrome. It is a derivative of the early insecticide DDT and an isomer of p,p'-DDD (4,4'-dichlorodiphenyldichloroethane) and is also known as 2,4'-(dichlorodiphenyl)-2,2-dichloroethane (o,p'-DDD).\u003c\/p\u003e\u003ch2\u003eMedical uses\u003c\/h2\u003e\u003cp\u003eMitotane has been produced by Bristol Myers Squibb but it is marketed as an orphan drug for adrenocortical carcinoma due to the small number of patients in need of it. Its main use is in those patients who have persistent disease despite surgical resection, those who are not surgical candidates, or those who have metastatic disease. In a 2007 retrospective study of 177 patients from 1985 to 2005 showed a significant increase in the recurrence-free interval after radical surgery followed by mitotane when compared to surgery alone. The drug is also sometimes used in the treatment of Cushing's syndrome.\u003c\/p\u003e\u003ch3\u003eWhy is this medication prescribed?\u003c\/h3\u003e\u003cp\u003eMitotane is used to treat cancer of the adrenal gland that can not be treated with surgery. Mitotane is in a class of medications called antineoplastic agents. It works by slowing growth or reducing the size of the tumor.\u003c\/p\u003e\u003ch3\u003eHow should this medicine be used?\u003c\/h3\u003e\u003cp\u003eMitotane comes as a tablet to take by mouth. It is usually taken three to four times a day. Take mitotane at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take mitotane exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\u003cp\u003eYou will probably be hospitalized when you begin your treatment with mitotane. Your doctor will start you on a low dose of mitotane and gradually increase your dose.\u003c\/p\u003e\u003cp\u003eContinue to take mitotane even if you feel well. Do not stop taking mitotane without talking to your doctor.\u003c\/p\u003e\u003ch3\u003eOther uses for this medicine\u003c\/h3\u003e\u003cp\u003eMitotane is also sometimes used to treat Cushing's Syndrome (condition where the body produces too much of the hormone cortisol). Talk to your doctor about the risks of using this drug for your condition.\u003c\/p\u003e\u003cp\u003eThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e\u003ch3\u003eWhat side effects can this medication cause?\u003c\/h3\u003e\u003cp\u003eMitotane may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eloss of appetite\u003c\/li\u003e\n\u003cli\u003enausea\u003c\/li\u003e\n\u003cli\u003evomiting\u003c\/li\u003e\n\u003cli\u003ediarrhea\u003c\/li\u003e\n\u003cli\u003edepression\u003c\/li\u003e\n\u003cli\u003elack of energy\u003c\/li\u003e\n\u003cli\u003eunusual drowsiness\u003c\/li\u003e\n\u003cli\u003efeeling that the room is spinning\u003c\/li\u003e\n\u003cli\u003echanges in vision\u003c\/li\u003e\n\u003cli\u003erash or changes in skin color.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797950132267,"sku":"RL1420230901667","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-09-169.jpg?v=1787022144"},{"product_id":"generic-cabozantinib-cabodx-20","title":"CABODX 20 (Cabozantinib)","description":"\u003cp\u003eCabozantinib is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.\u003c\/p\u003e\u003ch3\u003eMedullary Thyroid Cancer\u003c\/h3\u003e\u003cp\u003eCapsule only\u003c\/p\u003e\u003cp\u003eIndicated for treatment of progressive, metastatic medullary thyroid cancer (MTC)\u003c\/p\u003e\u003cp\u003e140 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003cp\u003eTablet only\u003c\/p\u003e\u003ch4\u003eCombination with nivolumab\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with nivolumab for first-line treatment of advanced renal cell carcinoma (RCC)\u003c\/li\u003e\n\u003cli\u003eCabozantinib 40 mg PO qDay PLUS nivolumab 240 mg IV q2Weeks or 480 mg IV q4Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eNivolumab only: Continue for up to 2 years\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eSingle agent\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for advanced RC\u003c\/li\u003e\n\u003cli\u003e60 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHepatocellular Carcinoma\u003c\/h3\u003e\u003cp\u003eTablet only\u003c\/p\u003e\u003cp\u003eIndicated for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib\u003c\/p\u003e\u003cp\u003e60 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003eDifferentiated Thyroid Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for locally advanced or metastatic differentiated thyroid cancer (DTC) in adults who have progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible\u003c\/p\u003e\u003cp\u003eBSA \u0026gt;1.2 m\u003csup\u003e2\u003c\/sup\u003e: 60 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDosage reductions (Cabometyx)\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eMonotherapy with BSA \u0026gt;1.2 m2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 40 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003ePreviously receiving 20 mg qDay: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 20 mg qDay: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIn combination with nivolumab\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO every other day\u003c\/li\u003e\n\u003cli\u003ePreviously receiving 20 mg every other day: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 20 mg every other day: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eWithhold dose until Grade ≤1 or until complete resolution\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade ≥2 diarrhea\u003c\/li\u003e\n\u003cli\u003eGrade 3 or intolerable grade 2 palmar-plantar erythrodysesthesia\u003c\/li\u003e\n\u003cli\u003eGrade 2 or 3 proteinuria\u003c\/li\u003e\n\u003cli\u003eAny grade osteonecrosis of jaw (ONJ)\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 or intolerable grade 2 other adverse reactions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eWithhold dose until Grade ≤1\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eTablet\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eConsider corticosteroid therapy if withheld or discontinued when administered in combination with nivolumab\u003c\/li\u003e\n\u003cli\u003eALT or AST \u0026gt;3x ULN but ≤10x ULN with concurrent total bilirubin [TB] \u0026lt;2x ULN\u003c\/li\u003e\n\u003cli\u003eAfter recovery, consider rechallenge with one or both of Cabometyx and nivolumab\u003c\/li\u003e\n\u003cli\u003eIf rechallenging with nivolumab with or without Cabometyx, refer to nivolumab prescribing information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eWithhold dose until adequately controlled at Grade ≤2\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 hypertension and hypertensive crisis\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003ePermanently discontinue\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrades 3 or 4 hemorrhage\u003c\/li\u003e\n\u003cli\u003eAny grade gastrointestinal perforation\u003c\/li\u003e\n\u003cli\u003eGrade 4 fistula\u003c\/li\u003e\n\u003cli\u003eAny grade acute myocardial infarction\u003c\/li\u003e\n\u003cli\u003eGrade ≥2 cerebral infarction\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 arterial thromboembolic events\u003c\/li\u003e\n\u003cli\u003eGrade 4 venous thromboembolic events\u003c\/li\u003e\n\u003cli\u003eGrade 4 hypertension or uncontrolled hypertensive crisis\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome\u003c\/li\u003e\n\u003cli\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/li\u003e\n\u003cli\u003eALT or AST \u0026gt;10x ULN or \u0026gt;3x ULN with concurrent TB ≥2x ULN; permanently discontinue both nivolumab and Cabometyx\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCYP3A4 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration with strong CYP3A4 inhibitors\u003c\/li\u003e\n\u003cli\u003eCometriq: If strong CYP3A4 inhibitor required, decrease cabozantinib dose by 40 mg\/day (eg, from 140 mg to 100 mg qDay)\u003c\/li\u003e\n\u003cli\u003eCabometyx: If strong CYP3A4 inhibitor required, decrease cabozantinib dose by 20 mg\/day (eg, from 60 mg to 40 mg qDay)\u003c\/li\u003e\n\u003cli\u003eResume previous dose 2-3 days after strong CYP3A4 inhibitor discontinued\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCYP3A4 inducers\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration of strong CYP3A4 inducers\u003c\/li\u003e\n\u003cli\u003eCometriq: If strong CYP3A4 inducer required, increase dose by 40 mg\/day (eg, from 140 mg to 180 mg qDay); do not exceed 180 mg\/day\u003c\/li\u003e\n\u003cli\u003eCabometyx: If strong CYP3A4 inducer required, increase dose by 20 mg\/day (eg, from 60 mg to 80 mg qDay); do not exceed 80 mg\/day\u003c\/li\u003e\n\u003cli\u003eResume previous dose 2-3 days after strong CYP3A4 inducer discontinued\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eTablet\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): Reduce starting dose to 80 mg\/day\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eTablet\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): Reduce starting dose to 40 mg\/day\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): No experience\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797951639595,"sku":"RL1720231021","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-10-3053.jpg?v=1787022156"},{"product_id":"generic-cabozantinib-cabodx-60","title":"CABODX 60 (Cabozantinib)","description":"\u003cp\u003eCabozantinib is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Medullary_Thyroid_Cancer\"\u003eMedullary Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eCapsule only\u003c\/p\u003e\u003cp\u003eIndicated for treatment of progressive, metastatic medullary thyroid cancer (MTC)\u003c\/p\u003e\u003cp\u003e140 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Renal_Cell_Carcinoma\"\u003eRenal Cell Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eTablet only\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Combination_with_nivolumab\"\u003eCombination with nivolumab\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with nivolumab for first-line treatment of advanced renal cell carcinoma (RCC)\u003c\/li\u003e\n\u003cli\u003eCabozantinib 40 mg PO qDay PLUS nivolumab 240 mg IV q2Weeks or 480 mg IV q4Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eNivolumab only: Continue for up to 2 years\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Single_agent\"\u003eSingle agent\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for advanced RC\u003c\/li\u003e\n\u003cli\u003e60 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Hepatocellular_Carcinoma\"\u003eHepatocellular Carcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eTablet only\u003c\/p\u003e\u003cp\u003eIndicated for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib\u003c\/p\u003e\u003cp\u003e60 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Differentiated_Thyroid_Cancer\"\u003eDifferentiated Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for locally advanced or metastatic differentiated thyroid cancer (DTC) in adults who have progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible\u003c\/p\u003e\u003cp\u003eBSA \u0026gt;1.2 m\u003csup\u003e2\u003c\/sup\u003e: 60 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_reductions_Cabometyx\"\u003eDosage reductions (Cabometyx)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Monotherapy_with_BSA_12_m2\"\u003eMonotherapy with BSA \u0026gt;1.2 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 40 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003ePreviously receiving 20 mg qDay: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 20 mg qDay: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"In_combination_with_nivolumab\"\u003eIn combination with nivolumab\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO every other day\u003c\/li\u003e\n\u003cli\u003ePreviously receiving 20 mg every other day: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 20 mg every other day: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_Grade_1_or_until_complete_resolution\"\u003eWithhold dose until Grade ≤1 or until complete resolution\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade ≥2 diarrhea\u003c\/li\u003e\n\u003cli\u003eGrade 3 or intolerable grade 2 palmar-plantar erythrodysesthesia\u003c\/li\u003e\n\u003cli\u003eGrade 2 or 3 proteinuria\u003c\/li\u003e\n\u003cli\u003eAny grade osteonecrosis of jaw (ONJ)\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 or intolerable grade 2 other adverse reactions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_Grade_1\"\u003eWithhold dose until Grade ≤1\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eConsider corticosteroid therapy if withheld or discontinued when administered in combination with nivolumab\u003c\/li\u003e\n\u003cli\u003eALT or AST \u0026gt;3x ULN but ≤10x ULN with concurrent total bilirubin [TB] \u0026lt;2x ULN\u003c\/li\u003e\n\u003cli\u003eAfter recovery, consider rechallenge with one or both of Cabometyx and nivolumab\u003c\/li\u003e\n\u003cli\u003eIf rechallenging with nivolumab with or without Cabometyx, refer to nivolumab prescribing information\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Withhold_dose_until_adequately_controlled_at_Grade_2\"\u003eWithhold dose until adequately controlled at Grade ≤2\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 hypertension and hypertensive crisis\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Permanently_discontinue\"\u003ePermanently discontinue\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrades 3 or 4 hemorrhage\u003c\/li\u003e\n\u003cli\u003eAny grade gastrointestinal perforation\u003c\/li\u003e\n\u003cli\u003eGrade 4 fistula\u003c\/li\u003e\n\u003cli\u003eAny grade acute myocardial infarction\u003c\/li\u003e\n\u003cli\u003eGrade ≥2 cerebral infarction\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 arterial thromboembolic events\u003c\/li\u003e\n\u003cli\u003eGrade 4 venous thromboembolic events\u003c\/li\u003e\n\u003cli\u003eGrade 4 hypertension or uncontrolled hypertensive crisis\u003c\/li\u003e\n\u003cli\u003eNephrotic syndrome\u003c\/li\u003e\n\u003cli\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/li\u003e\n\u003cli\u003eALT or AST \u0026gt;10x ULN or \u0026gt;3x ULN with concurrent TB ≥2x ULN; permanently discontinue both nivolumab and Cabometyx\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"CYP3A4_inhibitors\"\u003eCYP3A4 inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration with strong CYP3A4 inhibitors\u003c\/li\u003e\n\u003cli\u003eCometriq: If strong CYP3A4 inhibitor required, decrease cabozantinib dose by 40 mg\/day (eg, from 140 mg to 100 mg qDay)\u003c\/li\u003e\n\u003cli\u003eCabometyx: If strong CYP3A4 inhibitor required, decrease cabozantinib dose by 20 mg\/day (eg, from 60 mg to 40 mg qDay)\u003c\/li\u003e\n\u003cli\u003eResume previous dose 2-3 days after strong CYP3A4 inhibitor discontinued\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"CYP3A4_inducers\"\u003eCYP3A4 inducers\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration of strong CYP3A4 inducers\u003c\/li\u003e\n\u003cli\u003eCometriq: If strong CYP3A4 inducer required, increase dose by 40 mg\/day (eg, from 140 mg to 180 mg qDay); do not exceed 180 mg\/day\u003c\/li\u003e\n\u003cli\u003eCabometyx: If strong CYP3A4 inducer required, increase dose by 20 mg\/day (eg, from 60 mg to 80 mg qDay); do not exceed 80 mg\/day\u003c\/li\u003e\n\u003cli\u003eResume previous dose 2-3 days after strong CYP3A4 inducer discontinued\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet1\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): Reduce starting dose to 80 mg\/day\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Tablet2\"\u003eTablet\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): Reduce starting dose to 40 mg\/day\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): No experience\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797951672363,"sku":"RL1720231021","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-10-3072.jpg?v=1787022157"},{"product_id":"loqtorzi-toripalimab","title":"Loqtorzi (Toripalimab)","description":"\u003ch2\u003eAbout Toripalimab\u003c\/h2\u003e\u003cp\u003eToripalimab-tpzi is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD⁠-⁠1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eToripalimab  sold under the brand name LOQTORZI\u003csup\u003e®\u003c\/sup\u003e in Europe.\u003c\/li\u003e\n\u003cli\u003eToripalimab  sold under the brand name ZYTORVI\u003csup\u003e®\u003c\/sup\u003e in India.\u003c\/li\u003e\n\u003cli\u003eToripalimab  sold under the brand name 拓益\u003csup\u003e®\u003c\/sup\u003e in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eApproved\u003c\/h2\u003e\u003ch3\u003eOn October 27, 2023\u003c\/h3\u003e\u003cp\u003eThe FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).\u003c\/p\u003e\u003cp\u003eFDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.\u003c\/p\u003e\u003ch3\u003eSeptember 24, 2024\u003c\/h3\u003e\u003cp\u003eShanghai -- On September 24, 2024, Beijing time, Junshi Biosciences (1877.HK, 688180.SH) announced that the company's independently developed anti-PD-1 monoclonal antibody drug Toripalimab (European trade name: LOQTORZI®) has recently been approved by the European Commission (EC) for the treatment of two indications:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eToripalimab combined with cisplatin and gemcitabine is used for the first-line treatment of adult patients with recurrent, inoperable or radiotherapy-intolerant, or metastatic nasopharyngeal carcinoma (NPC);\u003c\/li\u003e\n\u003cli\u003eToripalimab combined with cisplatin and paclitaxel is used for the first-line treatment of adult patients with unresectable advanced\/recurrent or metastatic esophageal squamous cell carcinoma (ESCC).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Junshi Biosciences, China","offers":[{"title":"Default Title","offer_id":44797952229419,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-22100.jpg?v=1787022170"},{"product_id":"avzivi-bevacizumab","title":"Avzivi (Bevacizumab)","description":"\u003cp\u003eAvzivi® (Bevacizumab-tnjn)  sold under the brand name POBEVCY (普贝希) in China, is a humanized monoclonal antibody that targets VEGF. It specifically binds to VEGF and blocks the binding of VEGF to its receptor, thereby reducing neovascularization, inducing the degradation of existing blood vessels, and thereby inhibiting tumor growth. \u003c\/p\u003e\u003cp\u003eDec 7, 2023，The FDA has approved the fifth bevacizumab biosimilar, Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) for the treatment of several types of cancer. Avzivi\u003csup\u003e®\u003c\/sup\u003e (BAT1706) is Bio-Thera Solutions’ second FDA approved product in the United States. Avzivi\u003csup\u003e®\u003c\/sup\u003e is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.\u003c\/p\u003e","brand":"Bio-Thera Solutions, China","offers":[{"title":"Default Title","offer_id":44797952360491,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-2233.png?v=1787022174"},{"product_id":"generic-belzutifan-welidx","title":"WELIDX (Belzutifan)","description":"\u003ch2\u003eAbout  Belzutifan\u003c\/h2\u003e\u003cp\u003eBelzutifan is an hypoxia-inducible factor-2 alpha inhibitor. \u003c\/p\u003e\u003cp\u003eBelzutifan is used to treat von Hippel-Lindau (VHL) disease in patients who need treatment for kidney cancer (renal cell carcinoma), brain and spinal cord tumors (CNS hemangioblastomas), or pancreatic cancer (pancreatic neuroendocrine tumor [pNET]) that do not require surgery right away.\u003c\/p\u003e\u003ch2\u003eVon Hippel-Lindau Disease\u003c\/h2\u003e\u003cp\u003eIndicated for adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery\u003c\/p\u003e\u003cp\u003e120 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eRenal Cell Carcinoma\u003c\/h2\u003e\u003cp\u003eIndicated for advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)\u003c\/p\u003e\u003cp\u003e120 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eDosage Modifications\u003c\/h2\u003e\u003ch3\u003eDose reductions for adverse reactions\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 80 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 40 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird dose reduction: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eAnemia\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eHemoglobin \u0026lt;9 g\/dL or transfusion indicated: Withhold until hemoglobin ≥8 g\/dL; resume at same or reduced dose; or discontinue depending on severity of anemia\u003c\/li\u003e\n\u003cli\u003eLife-threatening or urgent intervention indicated: Withhold until hemoglobin ≥8 g\/dL; resume at a reduced dose or permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHypoxia\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eDecreased oxygen saturation with exercise (eg, pulse oximeter \u0026lt;88%): Consider withholding until resolved; resume at same dose or at reduced dose depending on severity\u003c\/li\u003e\n\u003cli\u003eDecreased oxygen saturation at rest (eg, pulse oximeter \u0026lt;88% or PaO\u003csub\u003e2\u003c\/sub\u003e ≤55 mm Hg) or urgent intervention indicated: Withhold until resolved; resume at reduced dose or discontinue depending on severity\u003c\/li\u003e\n\u003cli\u003eLife-threatening or recurrent symptomatic hypoxia: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eOther adverse reactions\u003c\/h3\u003e\u003cp\u003eGrade 3: Withhold until resolved to Grade ≤2; consider resuming at a reduced dose (reduce by 40 mg)\u003c\/p\u003e\u003cp\u003eRecurrent Grade 3 or Grade 4: Permanently discontinue\u003c\/p\u003e\u003ch3\u003eRenal impairment\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (eGFR 30-89 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR 15-29 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHepatic impairment\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin [TB] ≤ULN and AST \u0026gt;ULN or TB \u0026gt;1 to 1.5x ULN and any AST): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe hepatic impairment (TB \u0026gt;1.5x ULN and any AST): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of childbearing potential before initiation\u003c\/p\u003e\u003cp\u003eClosely monitor for adverse reactions in patients who are dual UGT2B17 and CYP2C19 poor metabolizers\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953343531,"sku":"RL3020241030","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2281.jpg?v=1787022200"},{"product_id":"lucitivo-tivozanib","title":"LuciTivo (Tivozanib)","description":"\u003ch2\u003eAbout Tivozanib\u003c\/h2\u003e\u003cp\u003eTivozanib  is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer).\u003csup id=\"cite_ref-FDA_tivozanib_3-1\" class=\"reference\"\u003e\u003c\/sup\u003eIt is an oral VEGF receptor tyrosine kinase inhibitor.\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003cp\u003eIndicated for relapsed or refractory advanced renal cell carcinoma in patients previously treated with ≥2 systemic therapies\u003c\/p\u003e\u003cp\u003e1.34 mg PO qDay on Days 1-21 of repeated 28-day cycles\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eIf dose modifications are required for adverse reactions, reduce to 0.89 mg qDay for 21 days followed by 7 days off treatment\u003c\/p\u003e\u003cp\u003eInitiate medical management for diarrhea, nausea, or vomiting prior to dose interruption or reduction\u003c\/p\u003e\u003ch4\u003eHypertension\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold for persistent Grade 3 despite optimal antihypertensive therapy\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose when hypertension controlled at Grade ≤2\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCardiac failure\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until improves to Grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose or discontinue depending on severity and persistence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eArterial thromboembolic events or reverse posterior leukoencephalopathy syndrome (RPLS)\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eHemorrhagic events\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eProteinuria\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e2 grams or greater proteinuria in 24 hr\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until less than or equal to 2 grams of proteinuria per 24 hr\u003c\/li\u003e\n\u003cli\u003eResume at a reduced dose\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue for nephrotic syndrome\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003ePersistent or intolerable Grade 2 or 3 OR Grade 4 laboratory abnormality\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eWithhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-severe (CrCl 15-89 mL\/min): No dosage modifications\u003c\/li\u003e\n\u003cli\u003eEnd-stage renal disease: Recommend dose not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin [TB] ≤1.5x ULN with any AST): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (TB \u0026gt;1.5 to 3x ULN with any AST): Reduce to 0.89 mg qDay\u003c\/li\u003e\n\u003cli\u003eSevere (TB 3 to 10x ULN with any AST): Not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy in females of reproductive potential before initiation\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954293803,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0821.jpg?v=1787022221"},{"product_id":"lucisuni-sunitinib","title":"LuciSuni (Sunitinib)","description":"\u003ch2\u003eAbout Sunitinib\u003c\/h2\u003e\u003cp\u003eSunitinib is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.\u003csup id=\"cite_ref-FDA_3-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eGastrointestinal Stromal Tumor\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate\u003c\/p\u003e\u003cp\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of advanced renal cell carcinoma (RCC)\u003c\/p\u003e\u003cp\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch4\u003eAdjuvant treatment of RCC\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy\u003c\/li\u003e\n\u003cli\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle for a total of nine 6-week cycles\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003ePancreatic Neuroendocrine Tumors\u003c\/h3\u003e\u003cp\u003eIndicated for progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease\u003c\/p\u003e\u003cp\u003e37.5 mg PO qDay continuously without a scheduled off-treatment period\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954752555,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0922.jpg?v=1787022227"},{"product_id":"luciaxi-axitinib","title":"LuciAxi (Axitinib)","description":"\u003ch2\u003eAbout Axitinib\u003c\/h2\u003e\u003cp\u003eAxitinib  is a small molecule tyrosine kinase inhibitor. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models\u003csup id=\"cite_ref-4\" class=\"reference\"\u003e\u003c\/sup\u003e and has shown partial responses in clinical trials with renal cell carcinoma (RCC)\u003cspan style=\"font-size: 13.3333px\"\u003e  \u003c\/span\u003eand several other tumour types.\u003csup id=\"cite_ref-6\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003ch4\u003eMonotherapy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for advanced renal cell carcinoma (RCC) in patients who failed 1 prior systemic therapy\u003c\/li\u003e\n\u003cli\u003e5 mg PO BID initially\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCombination therapy with avelumab\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with avelumab for first-line treatment of advanced RCC\u003c\/li\u003e\n\u003cli\u003eAxitinib 5 mg PO BID, plus\u003c\/li\u003e\n\u003cli\u003eAvelumab 800 mg IV q2Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eDuring combination therapy with avelumab, consider escalating dose of axitinib above 5 mg\/dose in 2-week intervals or longer\u003c\/li\u003e\n\u003cli\u003eRefer the prescribing information of avelumab for dosing information\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCombination therapy with pembrolizumab\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of advanced RCC\u003c\/li\u003e\n\u003cli\u003eAxitinib 5 mg PO BID, plus\u003c\/li\u003e\n\u003cli\u003ePembrolizumab 200 mg IV q3Weeks or 400 mg IV q6Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eDuring combination therapy with pembrolizumab, consider escalating dose of axitinib above 5 mg\/dose in 6-week intervals or longer\u003c\/li\u003e\n\u003cli\u003eRefer the prescribing information of pembrolizumab for dosing information\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954785323,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0927.jpg?v=1787022228"},{"product_id":"pazorest-200-mg-pazopanib-200-mg-as-pazopanib-hydrochloride","title":"Pazorest 200 mg (Pazopanib 200 mg (as pazopanib hydrochloride))","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-8 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003ePazorest 200 mg (Pazopanib)\u003c\/strong\u003e is a targeted anticancer medicine belonging to the \u003cstrong\u003etyrosine kinase inhibitor (TKI)\u003c\/strong\u003e class. It works by blocking specific proteins involved in tumor growth and the formation of new blood vessels that supply cancer cells. It is mainly used to treat \u003cstrong\u003eadvanced renal cell carcinoma (kidney cancer)\u003c\/strong\u003e and certain \u003cstrong\u003eadvanced soft-tissue sarcomas\u003c\/strong\u003e. It should be used under the supervision of an oncologist.\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"z-0 flex min-h-[46px] justify-start\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1\"\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44898317107243,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Pazorest.png?v=1787346122"},{"product_id":"lenvaxen-4-lenvatinib-mesylate-inn-equivalent-to-lenvatinib-4-mg","title":"Lenvaxen 4 (Lenvatinib Mesylate INN equivalent to Lenvatinib 4 mg)","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-3 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003eLenvaxen 4 is used for certain advanced cancers, including \u003cstrong\u003eradioactive-iodine-refractory differentiated thyroid cancer, advanced kidney cancer, unresectable liver cancer, and certain advanced endometrial cancers\u003c\/strong\u003e, depending on the treatment regimen and patient characteristics. Lenvatinib works by inhibiting several kinase pathways involved in tumor growth and blood-vessel formation. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eIt is a \u003cstrong\u003eprescription anticancer medicine\u003c\/strong\u003e and should be used under an oncologist's supervision.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"z-0 flex min-h-[46px] justify-start\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1\"\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45023187304491,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Lenvaxen4.jpg?v=1787513147"}],"url":"https:\/\/xomeds.com\/collections\/kidney-cancer.oembed","provider":"XOMEDS","version":"1.0","type":"link"}